Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.38 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | ASPH | Q12797 | 2/20 | 0.35 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802723 | 0.82 | ABCC8 (0.41) | GPR84ABCC8KCNJ11MMP3MEN1 | |
| SCHEMBL7074970 | 0.82 | ABCC8 (0.41) | GPR84ABCC8KCNJ11MMP3MEN1 | |
| SCHEMBL7957832 | 0.79 | TAAR1 (0.55) | TYMPGPR84ABCC8KCNJ11KDM4E | |
| SCHEMBL7077604 | 0.79 | ABCC8 (0.44) | ABCC8KCNJ11 | |
| SCHEMBL7077490 | 0.79 | ADRA2A (0.36) | ABCC8KCNJ11 | |
| SCHEMBL24050527 | 0.76 | TAAR1 (0.49) | TYMPGPR84ABCC8KCNJ11KDM4E | |
| SCHEMBL7067708 | 0.76 | TYMP (0.40) | TYMPGPR84MMP3ASPHKDM8 | |
| SCHEMBL24050513 | 0.76 | TAAR1 (0.56) | TYMPABCC8KCNJ11KDM4ETAAR1 | |
| SCHEMBL24050732 | 0.74 | TAAR1 (0.51) | TYMPTAAR1SIGMAR1ALDH1A1MEN1 | |
| SCHEMBL27491762 | 0.74 | ABCC8 (0.43) | ABCC8KCNJ11KDM4ETAAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1158290-C | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use | ŵ��Ų�ڿ˹�˾ | 2004-07-21 | — | — | CN | claimed |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | claimed |
| US-20030125323-A1 | Use of selective potassium channel openers | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | US | claimed |
| US-20030109519-A1 | Use of selective potassium channel openers | NOVO NORDISK (DK) | 2003-06-12 | — | — | US | claimed |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | NOVO NORDISK A/S (DK) | 2002-03-21 | — | — | US | claimed |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | claimed |
| CN-1208417-A | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use | NOVO NORDISK AS (DK) | 1999-02-17 | — | — | CN | claimed |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | disclosed |
| US-20030125323-A1 | Use of selective potassium channel openers | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | US | disclosed |
| US-20030109519-A1 | Use of selective potassium channel openers | NOVO NORDISK (DK) | 2003-06-12 | — | — | US | disclosed |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | NOVO NORDISK A/S (DK) | 2002-03-21 | — | — | US | disclosed |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | disclosed |
| US-5889002-A | CENTRAL NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS; ENDOCRINAL DISEASES | NOVO NORDISK A/S (DK) | 1999-03-30 | — | — | US | disclosed |
| CN-1208417-A | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use | NOVO NORDISK AS (DK) | 1999-02-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125323-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ1, KCNJ2 | TYMP 3917/4885GPR84 1053/4885ABCC8 73/4885 |
| US-20030109519-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ2, KCNJ1 | TYMP 3925/4885GPR84 1071/4885ABCC8 63/4885 |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | KCNN3, KCNN1, KCNN2 | TYMP 4073/4885GPR84 233/4885ABCC8 944/4885 |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | CD69, IAPP, CD4 | TYMP 1303/4885GPR84 219/4885ABCC8 3372/4885 |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | KCNN3, KCNN2, KCNN1 | TYMP 4790/4885GPR84 315/4885ABCC8 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.